This technology provides pharmaceutical and health supplement compositions for the prevention and treatment of ovarian and breast cancer, utilizing chrysophanol—an anthraquinone-based natural compound primarily found in rhubarb—in combination with the PI3K/AKT inhibitor LY294002 or the ERK1/2 inhibitor U0126.
Ovarian cancer lacks early diagnostic tools and frequently develops chemotherapy resistance, leading to a recurrence rate of approximately 70% in late-stage patients. Breast cancer is the second most common and deadly malignancy in women, yet advanced cases often show poor responses to surgery or chemotherapy, accompanied by significant side effects. While the anticancer effects of related anthraquinones like emodin and rhein are known, the effects of chrysophanol on gynecological cancers had not been previously reported.
This technology leverages the ability of chrysophanol to regulate PI3K/AKT and MAPK signaling pathways, thereby inhibiting the proliferation of ovarian and breast cancer cells and increasing apoptosis in a dose-dependent manner. By combining it with targeted inhibitors that focus on the same pathways, a synergistic effect on cell death is achieved. This approach can be applied to combination therapies for recurrent ovarian cancer, the development of treatments for advanced breast cancer, and anticancer screening using animal-derived cell lines, offering a strategy that reduces the toxicity associated with synthetic anticancer drugs alone.
This invention was developed with support from the Ministry of Science and ICT for research into the role of sideroxylin extracted from Callistemon viminalis in the prevention and treatment of gynecological cancers.
N/A
